Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.

European journal of haematology - 1 Dec 2015

Cançado Rodolfo, Melo Murilo R, de Moraes Bastos Roberto, Santos Paulo C J L, Guerra-Shinohara Elivira M, Chiattone Carlos, Ballas Samir K

Abstract excerpt

This open-label, prospective, phase 2 study evaluated the safety and efficacy of deferasirox (10 ± 5 mg/kg/d) in patients with hereditary hemochromatosis (HH) and iron overload refractory to or intolerant of phlebotomy. Ten patients were enrolled and all completed the 12-month treatment period. There were significant decreases from baseline to end of study (i.e., 12 months) in median serum ferritin (P < 0.001),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoates
Share to Erythrocyte Indices

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemochromatosis

Share to Hemochromatosis Protein

Share to Histocompatibility Antigens Class I

Share to Iron Chelating Agents

Share to Iron Overload

Share to Triazoles

Source

Identifiers

PMID: 25684349
DOI: 10.1111/ejh.12530

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.PMID 25684349Read ↗

Hereditary hemochromatosis: a review of the genetics, mechanism, diagnosis, and treatment of iron overload.Semantic proximity Read ↗

Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.Semantic proximity Read ↗

Diagnosis and treatment of hereditary hemochromatosis: an update.Semantic proximity Read ↗

Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.Semantic proximity Read ↗

Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.Semantic proximity Read ↗

Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases.Semantic proximity Read ↗

Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study.Semantic proximity Read ↗

Pharmacogenetic Study of Deferasirox, an Iron Chelating AgentSemantic proximity Read ↗

Iron chelators reverse organ damage in type 4B hereditary hemochromatosis: Case reports.Semantic proximity Read ↗

Iron chelation with deferasirox in a patient with de-novo ferroportin mutation.Semantic proximity Read ↗

A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis.Semantic proximity Read ↗

HJV hemochromatosis, iron overload, and hypogonadism in a Brazilian man: treatment with phlebotomy and deferasirox.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.